DJIA 18,037.97 -42.17 -0.23%
NASDAQ 5,060.25 -31.84 -0.63%
S&P 500 2,108.92 -8.77 -0.41%
market minute promo

Gilead Sciences (NASDAQ: GILD)

102.94 -0.76 (-0.73%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $102.94 -0.73%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $104.18
Previous Close $103.70
Daily Range $102.01 - $104.53
52-Week Range $72.77 - $116.83
Market Cap $153.3B
P/E Ratio 14.11
Dividend (Yield) $0.00 (0.0%)
Volume 10,809,698
Average Daily Volume 11,047,001
Current FY EPS $10.18

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary Rss Feed

3 Things to Watch with Gilead Sciences Inc.'s Q1 Earnings

Gilead's success in Q1 depends on these 3 factors.

Gilead and Bristol-Myers Reveal Positive Data on HCV Drugs - Analyst Blog

All You Need To Know About HCV From The EASL Conference This Weekend

Will Express Scripts (ESRX) Disappoint Earnings in Q1? - Analyst Blog

Looking Ahead of Wall Street: Apple, GoPro, Gilead Sciences

How To Use Levered Free Cash Flow And Revenue Growth To Analyze Stocks

Biotech Bubble Bursting? 3 Stocks I Want to Buy

Celgene Corporation, Amgen Inc., and Gilead Sciences Inc. may be good biotech stocks to buy on a sell-off.

Short Sellers Become More Wary of Big Biotech

3 'Safe' Biotech Picks

Can You Guess Which State Won't Pay for Hepatitis C Drugs?

One state decided to take a hard line stance against Gilead's pricey hep C drugs last year. And this decision may end up turning into a huge windfall for AbbVie's rival therapy. Here's why.

See More GILD News...

GILD's Top Competitors

GILD $102.94 (-0.73%)
Current stock: GILD
AMGN $162.38 (-3.29%)
Current stock: AMGN
CELG $114.72 (-3.37%)
Current stock: CELG
$0.00 (0.00%)
Current stock: